AB0050 DETECTION OF SERUM AND SYNOVIAL FLUID LEVELS OF VISFATIN DURING FLARE-UPS AND REMISSION OF PRIMARY OSTEOARTHRITIS OF THE KNEES

Background OA is the most common form of joint disease and a major contributor of disability in older people. OA is a chronic joint disease characterized by cartilage breakdown, bone remodeling, osteophyte development and synovial inflammation [1]. Adipose tissue expresses and secretes a large number of proteins that often share functional and structural properties of cytokines and are there classified as adipokines [2]. These include leptin, adiponectin, resistin, visfatin, and others. These factors are associated with inflammation and immune response. Visfatin is an adipokines identified in 2004 and was identified first as Pre B cell Colony Enhancing Factor [3]. Visfatin is a potent inducer of PGE2 release in both human and immature mouse articular chondrocytes, as a result of increased messenger prostaglandin E synthase and decreased 15 15prostaglandine dehydrogenase syntheses [4]. Objectives The aim of the study was to measure the level of visfatin in serum and synovial fluid from patients with knee osteoarthritis in flare-up and after they enter in remission. Methods: to achieve the target of our study 20 patients with OA of the knee in flare-up were selected from out-patients clinic. The patients were followed up every two weeks after the first setting until they entered into remission. Twenty normal controls age, sex and body mass index (BMI) matched were recruited. In the first setting all patients had their sera, and synovial fluid measured for Visfatin, in the second setting sera and synovial fluid (if any) was drawn for visfatin measurement. Measurement of Visfatin by (ELISA) for quantitative determination of human visfatin in biological fluids. Results Conclusion Visfatin was elevated both systemically and locally in the patients with knee OA, was elevated during flare-ups and decrease during remission, was higher in serum than in synovial fluid of patients and There was no difference in the level of visfatin in relation to aging or gender difference. References [1] Lorenz H, Richter W (2006) Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog Histochem Cytochem40(3):135–163. [2] Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab89(6):2548–2556. [3] O. Gualillo, J. R. Gonźalez-Juanatey, and F. Lago,(2007) “The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives,” Trends in Cardiovascular Medicine, vol. 17, no. 8, pp. 275–283, 2007. [4] Duan Y, Hao D, Li M, et al. (2012) Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis. Rheumatol Int2012; 32:985–90. Disclosure of Interests None declared